Literature DB >> 26866707

THE IMPACT OF AGE IN THE MANAGEMENT OF HYPOTHYROIDISM: RESULTS OF A NATIONWIDE SURVEY.

Maria Papaleontiou, Brittany L Gay, Nazanene H Esfandiari, Sarah T Hawley, Megan R Haymart.   

Abstract

OBJECTIVE: Evidence exists that thyroid-stimulating hormone (TSH) increases with age and lowering the TSH goal in older patients on thyroid hormone may cause over-treatment. Risks of overtreatment include cardiac and skeletal events. We assessed practice patterns regarding TSH goals and explored factors influencing physicians' decision making when managing hypothyroidism.
METHODS: Members of the American College of Physicians, the American Academy of Family Practice, and the Endocrine Society were surveyed to determine goal TSH when treating hypothyroidism.
RESULTS: Fifty-three percent of physicians reported factoring patient age into their decision making when managing hypothyroidism. Patient age was prioritized third (53%), following patient symptoms (69.2%) and cardiac arrhythmias (65.7%). In multivariable analysis, endocrinologists (P = .002), internists (P = .049), physicians in academic settings (P = .003), and high-volume physicians (P = .021) were more likely to consider patient age when determining goal TSH. When presented with scenarios differing in patient gender and age, 90% of physicians targeted a TSH ≤3.0 mIU/L in 30-year-old patients. Fifty-three percent of respondents targeted a TSH ≤3.0 mIU/L in octogenarians, but 90% targeted a TSH >1.5 mIU/L in this group. Regardless of gender, physician-reported TSH goal ranges (0.1 to 0.5, 0.6 to 1.5, 1.6 to 3.0, and 3.1 to 5.0 mIU/L) increased in a direct relationship to patient age (P<.001).
CONCLUSION: Just over half of physicians consider patient age when determining TSH goal. When presented with scenarios differing in patient age and gender, physicians targeted a higher TSH goal in octogenarians. This may indicate an attempt to avoid overtreatment in this group. Consensus is needed among physicians regarding the role of patient age in hypothyroidism management. ABBREVIATIONS: TSH = thyroid-stimulating hormone.

Entities:  

Year:  2016        PMID: 26866707      PMCID: PMC5432199          DOI: 10.4158/EP151021.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  27 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; E H Hoogendoorn; W M van der Deure; Albert Hofman; R P Peeters; W C J Hop; M den Heijer; Theo J Visser; Jacqueline C M Witteman
Journal:  Arch Intern Med       Date:  2008-11-10

3.  An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits.

Authors:  Laura Boucai; Joseph G Hollowell; Martin I Surks
Journal:  Thyroid       Date:  2010-11-08       Impact factor: 6.568

Review 4.  Age- and race-based serum thyrotropin reference limits.

Authors:  Martin I Surks; Laura Boucai
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

5.  Genetic predisposition to elevated serum thyrotropin is associated with exceptional longevity.

Authors:  Gil Atzmon; Nir Barzilai; Martin I Surks; Ilan Gabriely
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

6.  Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.

Authors:  C T Sawin; A Geller; P A Wolf; A J Belanger; E Baker; P Bacharach; P W Wilson; E J Benjamin; R B D'Agostino
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

7.  Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study.

Authors:  Peter N Taylor; Ahmed Iqbal; Caroline Minassian; Adrian Sayers; Mohd S Draman; Rosemary Greenwood; William Hamilton; Onyebuchi Okosieme; Vijay Panicker; Sara L Thomas; Colin Dayan
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

8.  Extreme longevity is associated with increased serum thyrotropin.

Authors:  Gil Atzmon; Nir Barzilai; Joseph G Hollowell; Martin I Surks; Ilan Gabriely
Journal:  J Clin Endocrinol Metab       Date:  2009-01-21       Impact factor: 5.958

9.  Levothyroxine dose and risk of fractures in older adults: nested case-control study.

Authors:  Marci R Turner; Ximena Camacho; Hadas D Fischer; Peter C Austin; Geoff M Anderson; Paula A Rochon; Lorraine L Lipscombe
Journal:  BMJ       Date:  2011-04-28

10.  Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women.

Authors:  Young-Jin Ko; Ji Young Kim; Joongyub Lee; Hong-Ji Song; Ju-Young Kim; Nam-Kyong Choi; Byung-Joo Park
Journal:  J Prev Med Public Health       Date:  2014-01-29
View more
  2 in total

1.  Understanding Worry About Risks Associated With Thyroid Hormone Therapy: A National Survey of Endocrinologists, Family Physicians, and Geriatricians.

Authors:  Kimi Shah; David Reyes-Gastelum; Brittany L Gay; Maria Papaleontiou
Journal:  Endocr Pract       Date:  2021-08-24       Impact factor: 3.443

Review 2.  Biochemical Testing in Thyroid Disorders.

Authors:  Nazanene H Esfandiari; Maria Papaleontiou
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-08       Impact factor: 4.741

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.